• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

554.73 -4.37 (-0.78%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 531,785
Open 561.20
Bid (Size) 545.00 (40)
Ask (Size) 553.00 (40)
Prev. Close 559.10
Today's Range 551.76 - 563.12
52wk Range 455.63 - 614.23
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease
November 20, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter ↗
November 16, 2026
United Therapeutics (NASDAQ:UTHR) is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a... 
Via MarketBeat

Performance

52-Week Range 9.7% below 52-week high
554.73
455.6352W Low 614.2352W High
1 Week 6.9% below 1-week high
551.761W Low 595.661W High

United Therapeutics Corporation - Common Stock (UTHR) traded between $455.63 and $614.23 over the past 52 weeks and last traded at $554.73, 9.7% below its 52-week high. Over the past week it ranged between $551.76 and $595.66.

Past 12 Months
-5.6%
-1.6%
+8.1%
-2.4%
+11.7%
+16.9%
1W -$33.15
1M -$8.76
3M +$41.61
6M -$13.70
YTD +$58.01
1Y +$80.01

UTHR was +16.9% over the past year, -2.4% over six months, +11.7% year to date, -5.6% in the last week.

12 Months vs Market
UTHR
+16.9%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months UTHR returned +16.9% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.76× 3-mo avg
Today 531,785 3-mo avg 701.1K
1W
441.7K
1M
509.4K
3M
701.1K
6M
609.0K
YTD
552.2K
1Y
540.1K

UTHR most recently traded 531,785 shares against a 3-month average daily volume of 701.1K.

More News

Read More
News headline image
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
November 09, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
The 5 most interesting analyst questions from United Therapeutics’s Q3 2026 earnings call
November 06, 2026
Via StockStory
Topics Earnings
United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings ↗
November 04, 2026
Via Chartmill
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price ↗
October 19, 2026
Via Chartmill
News headline image
UTHR Q3 2026 deep dive: margin compression and product pipeline updates shape outlook
November 05, 2026
Via StockStory
Topics Intellectual Property
News headline image
What United Therapeutics (UTHR) Said on Its Q3 Earnings Call ↗
November 04, 2026
Via MarketBeat
Topics Earnings Supply Chain
News headline image
United Therapeutics (UTHR) Q3 2026 Earnings Call Transcript ↗
November 04, 2026
Via The Motley Fool
Topics Earnings
News headline image
United Therapeutics Announces Buydown of Ralinepag Royalty
November 04, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (NASDAQ:UTHR) beats Q3 2026 sales expectations, stock soars
November 04, 2026
Via StockStory
News headline image
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
November 04, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
November 02, 2026
Via StockStory
News headline image
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
October 28, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
2 healthcare stocks to keep an eye on and 1 that underwhelm
October 23, 2026
Via StockStory
News headline image
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
October 22, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
October 21, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
October 20, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
October 19, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Market-Beating Stocks for Long-Term Investors
October 19, 2026
Via StockStory
News headline image
2 Cash-Producing Stocks on Our Watchlist and 1 We Avoid
October 16, 2026
Via StockStory
News headline image
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
October 13, 2026
From United Therapeutics
Via Business Wire
News headline image
3 Reasons to Avoid UTHR and 1 Stock to Buy Instead
October 07, 2026
Via StockStory
News headline image
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
October 01, 2026
Via StockStory
Topics Intellectual Property
News headline image
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
October 01, 2026
Via StockStory

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 554.73
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 24.90B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 25B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap